Advanced Cancer Clinical Trials in Dallas, Texas

5 studies are recruiting for advanced cancer in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mary Crowley Cancer Research, Dallas, Texas
    Locations
    82 in total
    Run by
    Artios Pharma Ltd

    See if you can join NCT04657068 on ClinicalTrials.gov

  2. Phase 1/2 Study of UI-102 in Selected Advanced Cancers

    This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEXT Oncology, Dallas, Texas
    Locations
    3 in total
    Run by
    United Immunity, co., Ltd.

    See if you can join NCT07605962 on ClinicalTrials.gov

  3. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Next Oncology, Dallas, Texas
    Locations
    18 in total
    Run by
    Incyclix Bio

    See if you can join NCT05735080 on ClinicalTrials.gov

  4. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

    This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mary Crowley Cancer Research, Dallas, Texas
    Locations
    21 in total
    Run by
    I-Mab Biopharma US Limited

    See if you can join NCT04900818 on ClinicalTrials.gov

  5. Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

    Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mary Crowley Cancer Research, Dallas, Texas
    Locations
    11 in total
    Run by
    Qurient Co., Ltd.

    See if you can join NCT05394103 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.